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Summary 
CD40 is known as an important T-B cell interaction molecule which rescues B lymphocytes 
from undergoing apoptosis. Like other receptors of the tumor necrosis factor (TNF) receptor 
gene family, CD40 is expressed on cells of different tissue origins including some transformed 
cells. In contrast to its well-studied effects on B cells, the biological functions of CD40 in non- 
immune cells  remain largely unknown.  Here we show that CD40 ligation induces apoptotic 
cell death in transformed cells of mesenchymal and epithelial origin. This CD40-mediated cell 
death seems to use a preformed signaling pathway since it occurs even when protein synthesis is 
blocked.  Notably,  the  CD40  cytoplasmic domain shares a  structural  homology with  the re- 
cently  defined  "death  domains"  of the  55-kD  TNF  receptor  (p55TNFR)  and  Fas.  Despite 
these structural similarities, differences are seen in the way phorbol myristate acetate, interleu- 
kin  1, TNF,  and various metabolic inhibitors influence the  cellular responsiveness to CD40, 
p55TNFR,  and Fas-mediated killing.  Our study indicates that CD40 induces celt death by a 
distinct mechanism. 
p }rogrammed  cell  death  (apoptosis)  serves  as  a  crucial 
control mechanism not only during embryogenesis for 
the development of organs but also in the mature organism 
for the maintenance of tissue homeostasis. In the immune 
system the development of T  and B  lymphocytes depends 
on a selection process involving the controlled triggering of 
cell death  (reviewed in  [1]).  CTL also  eliminate their tar- 
gets via specific induction  of cell death  (reviewed in  [2]). 
The broadly expressed receptors Fas/APO-1 (3, 4) and 55-kD 
TNF  receptor  (p55TNF1K)  (5-7),  both  members  of the 
TNF1K gene family, function as membrane triggers for apo- 
ptosis  in  various  target  cells  that  are  susceptible  to  CTL, 
e.g., virus-infected or cancer cells (8). 
For both p55TNF1K and Fas, a motif spanning 65 amino 
acids within  the  cytoplasmic regions is essential and sufti- 
cient for their cytotoxic function and has been named the 
death domain (9,  10).  A similar motif was found in the cy- 
toplasmic domain of CD40, which belongs to the same re- 
ceptor family (4,  11).  However, in B  lymphocytes CD40 
provides signals  that rescue them from apoptotic death and 
therefore has been aptly described as an antiapoptotic mol- 
ecule  (12-14).  The ligand of CD40  (CD40L) 1 is a type II 
transmembrane molecule with a homology to TNF, lym- 
photoxin-ot  and  [3,  and  the  Fas  ligand  (15-17);  it  is  ex- 
pressed  on  activated  T  lymphocytes.  The  interaction  of 
CD40  and  CD40L is crucial for many other B  cell func- 
tions,  including  isotype  switching  (18),  short-  and  long- 
1Abbreviations used in  this paper: BHA, butylated hydroxyanisole; BHK, 
baby hamster kidney; BHKcD40L, BHK cells transfected with CD40L 
cDNA; BHKwt, BHK wild-type cells; CD40L, ligand of CD40; CHX, 
cycloheximide; NF-KB, nuclear factor KB; SN, supematants. 
term proliferation  (19,  20),  homotypic adhesion  (21),  and 
the  upregulation  of BT/BB-1  (CDS0)  (22).  Interestingly 
the  hyper  IgM  syndrome,  a  severe  immunodeficiency 
which  is  characterized  by  an  isotype  switch  defect,  was 
found  to  result from a  mutated  CD40L  gene  (23-26).  A 
similar defect was seen in CD40- or CD40L-deficient mice 
(27,  28). 
Intracellular signals delivered via CD40 in B cells include 
the activation of several serine and threonine specific pro- 
tein  kinases  (29,  30),  the  phosphorylation  of src  type ki- 
nases and of the phospholipase C'y2 and the phosphatidyl- 
inositol-3  kinase  (31).  The  first  clues  of how  CD40  is 
coupled  to intracellular  signaling pathways were  obtained 
with the yeast two-hybrid technique.  A  protein, variously 
named CD40bp, CRAF1, or LAP1, is apparently constitu- 
tively associated  with  CD40  (32-34)  and  plays  a  role  in 
CD40-mediated  upregulation  of  CD23  in  the  Burkitt's 
lymphoma cell line 1Kamos (35). 
Like the TNF1K and Fas, CD40 is not only expressed on 
hematopoietic cells but also on dendritic cells  (36),  thymic 
epithelium (37),  basal epithelium as well as on carcinomas 
and  other  transformed  cells  (11,  38-40).  However,  the 
functional properties and signaling mechanisms of CD40 in 
non-B cells are largely unknown. We have recently shown 
that  CD40  induces  nuclear  factor-KB  (NF-KB)  and  IL-6 
production  in  a human fibroblast cell line  and in  CD40- 
transfected  HeLa  cells  (41).  CD40  shares  these  functions 
with the p55TNF1K and Fas (42). As the CD40 cytoplasmic 
domain and the  death  domains of the p55TNF1K and Fas 
are  homologous  we  were  interested  to  know  whether 
CD40 might also induce signals leading to cell death. 
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induces apoptosis in transformed cells of mesenchymal and 
epithelial origin. The strongest effect was seen with mem- 
brane-bound  CD40L.  IFN-~/  treatment  rendered  unre- 
sponsive cells with low level CD40  expression susceptible 
to CD40-mediated cytotoxicity. CD40 stimulation seemed 
to  trigger a  preformed  death  program.  Despite  the  struc- 
tural homology to  Fas and  the p55TNFR,  we found that 
reagents  that  modulate  p55TNFR  or  Fas-mediated  ceil 
death affected CD40 killing in a unique way. This indicates 
that CD40 signals cell death through a distinct pathway. 
Materials  and Methods 
Cell Lines.  The murine L cell derivative A9 (43) was grown 
in ILPMI 1640;  the SV40-transformed human fibroblast cell line 
SV80 (44), the cervical carcinoma cell line HeLa (CCL 2; Ameri- 
can  Type  Culture  Collection,  !Kockville, MD)  and  the  baby 
hamster kidney (BHK) cells (ACC 61; German Collection of Mi- 
cro-organisms and Cell Cultures, Braunschweig, Germany) were 
cultured in DMEM. The culture media were supplemented with 
10% heat-inactivated FCS (Biochrom, Berlin, Germany), 100 U/ 
ml penicillin, 0.1  mg/ml streptomycin, 1 mM sodium pyruvate, 
and 2 mM L-alanyl-e-glutamine.  All supplements and culture me- 
dia were purchased from Gibco BRL (Eggenstein, Germany). 
Cloning of CD40 and CD40L cDNA and Transfection.  CD40 
cDNA was cloned by reverse transcriptase PC1K using total 1KNA 
isolated from IM-9 cells as previously described (45).  For expres- 
sion, the CD40 cDNA was ligated into the mammalian expres- 
sion vector pEF-BOS  (46)  and  designated BOS-CD40.  SV80, 
HeLa,  and A9  cells  were  cotransfected with  25  I.tg of ApaLI- 
digested BOS-CD40 and 2.5 lag ofHindlII-digested  pTCF plasmid 
encoding  a  neomycin  resistance  gene.  Transfection  was  per- 
formed with lipofectin (Gibco BRL) according to the manufac- 
turer's instructions.  Neomycin-resistant clones were  selected in 
0.6 mg/ml G418 for A9, 0.8 mg/ml for SV80, and l  mg/ml for 
HeLa  transfectants.  The  selected A9,  SV80,  and  HeLa  clones 
were tested for CD40 expression using an mAb against CD40 at 5 
btg/ml (G28-5  {19]) or anti-CD4 mAb (MT413)  as an isotype- 
matched control. After staining with FITC-conjugated goat anti- 
mouse  F(ab')2 fragment  (Dianova, Hamburg,  Germany) as sec- 
ondary  antibody,  the  CD40  expression  was  assessed  by  flow 
cytometry  (FACScan  |  Becton  Dickinson  and  Co.,  Mountain 
View, CA). 
Cloning of the CD40L cDNA and transfection into BHK cells 
were done as described previously (45). 
Cytokines and Reagents.  CD40L was used either in its cell sur- 
face (membrane-bound CD40L mCD40L)  or in a soluble form. 
BHK cells transfected with CD40L cDNA (BHKcD40L) or BHK 
wild-type  cells  (BHKwt)  as  a  control  were  fixed  with  3% 
paraformaldehyde in PBS  for  10  min,  followed by six washing 
steps  with PBS. This procedure prevented the attachment of the 
BHK cells to the microtiter plates, which might interfere with the 
determination of the target cell viability in cytotoxicity assays. 
For the production  of CD40L  supernatants  (SN)  or control 
SN, BHKcD40  L cells or BHKwt were grown to subconfluency. Af- 
ter two washes with PBS, serum-free Hybridoma SFM medium 
(Gibco BILL)  was added; 24  h  later the  culture SN were har- 
vested, centrifuged, and filtered at 0.2 lain. The SN were pooled, 
concentrated in a  Centriprep-10 or Centricon-10 concentrator 
(Amicon, Witten, Germany) and stored at -80~ 
Recombinant  human  TNF  was  a  gift  from  Dr.  G.  Adolf 
(Bender and Co.  GmbH,  Wien, Austria). IFN-y was a present 
from Dr. W. Wolf (Rentschler-Biotechnologie, Laupheim, Ger- 
many).  Recombinant  human  IL-I~  was  kindly provided  by 
Dr. C. A. Dinarello (Tufts University School of Medicine, Bos- 
ton, MA). 
Cycloheximide (CHX), PMA, butylated hydroxyanisole (BHA), 
the calcium ionophore A23187, vanadate, trifluoperazine, and all 
other  reagents  were  purchased  from  Sigma  Chemical  Co. 
(Deisenhofen, Germany) unless indicated otherwise. 
Antibodies.  Protein G  (Pharmacia, Freiburg, Germany) puri- 
fied anti-CD40 mAb G28-5 (IgG  0  was used for CD40 stimula- 
tion. The anti-p55TNFiL mAb htr-9 (IgG1) (47) was a gift from 
Dr. M. Brockhaus (Hoffmann Lalkoche, Basel, Switzerland), hu- 
manized monoclonal  mouse  antibody against Fas  (lgG3)  was  a 
present from Dr. John Grayebh (Centocor, Malvern, PA). Puri- 
fied  murine  myeloma  immunoglobulins  (IgGt,  MOPC  21) 
(Sigma Chemical Co.) and anti-CD4 mAb (MT413, lgG,, kindly 
provided by Dr.  E.  P.  ILieber, Institute for Immunology, Mu- 
nich, Germany), were used as control antibodies. Polyclonal anti- 
CD40L antibodies were raised against a fusion protein consisting 
of the  extracellular domain  of the  murine  IL-4  receptor and 
CD40L as described previously (45). 
Cytotoxicity Assay.  Target cells were seeded in gelatin-coated 
flat-bottom microtiter plates (Greiner, Niirtingen, Germany) ei- 
ther untreated or after a 2-d pretreatment with 1,000 U/mI IFN-T. 
Cells were seeded at densities of I  ￿  104 cells/well for assays per- 
formed in the absence of CHX and of 3  ￿  104 cells/well for as- 
says done in  the presence of CHX.  The  cells were allowed to 
grow for 24 h  (the medium for IFN-y pretreated cells contained 
1,000  U/ml IFN-y) and then challenged with serial dilutions of 
the stimulation reagents, either in the presence (50 lag/ml) or the 
absence of CHX. Cell viability  was assessed 16-18 h later (48 h in 
assays without CHX) by the neutral red uptake method accord- 
ing to Finter et al. (48) as described previously (45). 
Acridine Orange Staining.  Acridine orange  (Sigma Chemical 
Co.)  was added to the cells at 10 ng/ml in medium for 5 min. 
The culture plates were briefly centrifuged at 150 g and the dye 
was carefully replaced by Hank's salt solution (Biochrom, Berlin, 
Germany). The cellular morphology was analyzed using a fluores- 
cence  microscope  and  photographs  were  taken  at  a  400-fold 
magnification. 
Results 
CD4OL-CD40  Interaction Induces  Cell  Death  in  Trans- 
formed Cells of Mesenchymal and Epithelial Origin.  In many 
transformed cell lines ligation of Fas or the TNFR  leads to 
apoptotic cell death. Thus far, CD40's main role was seen 
as  that  of a  molecule with  antiapoptotic qualities.  This  is 
indeed surprising because its cytoplasmic domain is homol- 
ogous to the central part of the death domains of Fas and 
the p55TNF1L  (Fig. 1).  To investigate the functional rele- 
vance  of this  structural  similarity we  studied  CD40  re- 
sponses  in  the  TNF-sensitive  fibroblast  cell  line  SV80, 
which expresses low levels of CD40.  In previous studies it 
was shown that CD40, the p55TNFR and Fas (41, 42) sig- 
nal NF-KB mobilization and IL-6 production in these cells. 
It was  also seen  that  IFN-y pretreatment  enhanced  these 
CD40-mediated  effects.  Here  we  found  that  the  IFN-y- 
pretreated SV80  cells died rapidly in response to CD40  li- 
ration when protein synthesis was blocked with CHX  (Fig. 
160  CD40 Induces Apoptosis Figure 1.  Schematic  presentation of the intracel- 
lular  domains of  CD40,  p55TNFR,  and  Fas/ 
APO-1.  Homologous  regions  between  CD40 
(K22s--Q277),  the  p55TNFP,  (K343-I40s), and  Fas 
(K230-I294)  are  shown in gray. At the  amino acid 
level these regions show  a chemical similarity of 
26% for CD40 and p55TNFR, 39% for CD40 and 
Fas, and 45% for p55TNFP, and Fas. In p55TNFK and Fas the homology regions are found within the "death domains" (P327-L412 for p55TNFP- and 
D210-$304 for Fas, shown in black) as defined by Tartaglia et al. (9) and Itoh et al. (10). Similar amino acids were defined as follows: A, G; S, T; E, D; P,, 
K, H; Q, N; V, I, L, M; Y, F; W; P; C. (TMD, transmembrane domain). 
2/3).  BHKcD40  L killed up to 40% of the IFN-~/-pretreated 
targets while CD40L-negative control effector cells (BHKwt) 
had only a marginal effect on the viability of the SV80 cells. 
IFN-~/ pretreatment  of the  SVS0  cells was  necessary to 
induce susceptibility to CD40L.  At the molecular level the 
sensitizing effect of IFN-~/may be explained in two ways: 
IFN-'y upregulates cell surface CD40 expression (see Fig. 2 A) 
but  it  may  also  induce  intracellular changes  that  increase 
the  sensitivity to  CD40-mediated  killing.  To  distinguish 
between  these  possibilities  we  overexpressed  CD40  in 
SV80  cells  (SV80cD40)  by  transfection.  In  addition,  we 
transfected the  CD40  cDNA into the  CD40-negative hu- 
man cervical carcinoma cell line HeLa  (HeLacD40)  and the 
murine L  cell derivative A9  (A9cD40)  (Fig. 3  A). Both cell 
lines  have  been  characterized  extensively with  respect  to 
their TNF responses. Two CD40-expressing clones of each 
cell  line  were  compared.  Membrane  CD40L  efficiently 
killed the CD40  transfectants in a  dose-dependent manner 
(Fig.  3  B)  demonstrating  that  CD40-mediated  signals are 
sufficient to  induce  cell  death.  In  the  presence  of CHX, 
SVSOcD4o  and  A9cD4o  responded  to  a  similar extent  (40- 
50%  killing)  (Fig.  3  /3)  as  IFN-~/-pretreated SV80  wild- 
type cells (Fig. 2  B).  In HeLacD40 killing was almost com- 
plete (Fig. 3/3). 
Several control experiments demonstrated that the cyto- 
toxic effect of BHKcD40  L cells was indeed CD40 mediated: 
(a)  stimulation with mCD40L  had no  significant effect on 
the viability of CD40-negative wild-type cells (not shown) 
or mock transfectants  (Fig. 3  B).  (b)  The  cytotoxic effect 
of  BHKcD40 L  could  be  blocked  by  pretreatment  with 
anti-CD40L  antibodies  (data  not  shown).  (c)  SN  from 
BHKcD40  L cells containing a  soluble form of CD40L  were 
also  cytotoxic whereas  control SN  from BHI~,  cells had 
no  effect (data not shown).  (d)  In addition to  CD40L,  the 
anti-CD40 mAb G28-5, but not an isotype-matched con- 
trol  antibody,  elicited a  cytotoxic response  in  the  CD40 
transfectants, although the effect was weaker than that seen 
with mCD40L  (Fig. 3  B, b, d, and f). 
Acridine orange  staining was used  to  assess the form of 
cell death induced via CD40.  Microscopic examination of 
the stained cells of all three cell types revealed a typical ap- 
optotic  morphology after  CD40  ligation showing  cellular 
shrinkage, chromatin condensation, and clear nuclear frag- 
mentation  (Fig.  3  B,  b,  d,  and J].  This  demonstrated  that 
CD40 mediated an apoptotic form of cell death. 
Influence of Protein  Synthesis on  CD40  Killing.  SV80 and 
HeLa  cells are killed by  CD40,  p55TNFR,  and  Fas only 
when  protein synthesis is blocked.  In the  case of TNFR- 
mediated cytotoxicity this was  explained by the  constitu- 
tive  expression  of  resistance  proteins  (49).  In  contrast, 
mouse  A9  cells are sensitive to  TNF  and  Fas cytotoxicity 
even in the absence of protein or RNA  synthesis inhibitors. 
Therefore,  we  tested  the  response  to  CD40  ligation  in 
A9CD40  cells  with  intact  protein  synthesis.  Membrane 
CD40L  (Fig. 4, left), a soluble form of CD40L  (not shown) 
and  anti-CD40  antibodies  had  strong  cytotoxic  effects. 
CD40-killed cells again displayed a  typical apoptotic mor- 
phology (Fig. 4, inset). Unexpectedly, CD40-mediated kill- 
ing was  even more  effective in A9  cells in the  absence  of 
CHX:  a dose of mCD40L which induced complete killing 
of the  A9cD40  cells in  the  absence  of CHX  left  50%  of 
the  target  cells viable when  protein synthesis was  blocked 
(Fig. 4,  left).  This  was  in  clear contrast  to  p55TNF1L  and 
Fas, which killed A9 cells with intact protein synthesis 100- 
fold  (p55TNFR)  and  10-fold  (Fas)  less eff￿  (Fig.  4, 
middle  and right).  Thus it appeared that the mechanisms by 
which  CD40  induced cell death were  different from both 
p55TNFR.- and Fas-mediated killing. 
Figure 2.  CD40 hgation is cytotoxic for IFN-3,- 
treated transformed fibroblasts. (A) CD40 expression 
in untreated SV80 cells (11) or after treatment with 
1,000 U/ml IFN-'y for 3  d  (11) as determined by 
immunostaining with  the  anti-CD40  mAb  G28-5 
(11, II) or an isotype-matched control mAb ([ii~), 
FITC-conjugated  goat anti-mouse  F(ab')2 antibod- 
ies, and analysis  with a FACScan  |  (B) Two IFN-3,- 
treated subclones of SV80 were seeded in microtiter 
plates at a density of 3 ￿  104  cells/well. 24 h later 
paraforrnaldehyde-fixed BHKcD40L cells (11, 0)  or 
BHKwt cells (￿9  IN) were added at the indicated ef- 
fector cell doses in the presence of 50 txg/ml CHX. 
Viability of the target cells was determined after 18 h 
by the neutral red uptake method. Presented are the 
mean values of duplicate determinations of one rep- 
resentative experiment. 
161  Hess and Engelmann Figure 3.  CD40 mediates cell death in SV80, HeLa, and A9 cells trans- 
fected with  CD40  cDNA.  (A)  CD40  expression in  CD40-transfected 
SV80, HeLa, and A9 cells as determined by immunostaining with anti- 
CD40 mAb G28-5  (i,  B) or an isotype-matched control mAb ([[[]), 
FITC-conjugated goat anti-mouse F(ab')2 antibodies and analysis  with a 
FACScan  |  Two  individual clones (1  l,  2  m)  of each cell type are 
shown.  (B)  CD40-mediated  killing  was  tested  in  two  independent 
SV80co40, HeLacD40, and A9co40 clones (I O, 2 i,  left). The cells were 
challenged with  paraformaldehyde-fixed BHKcD40  L (0,  i)  or BHKwt 
cells as a control (O, [~) at the indicated effector cell doses in the presence 
of 50 txg/ml CHX.  18 h later the viability was determined by the neutral 
red uptake method. Presented are the mean values of duplicate determi- 
nations of one representative experiment. The black bars indicate the ef- 
fect ofBHKco40  L cells (1.8 ￿  105 cells/well) on the corresponding mock 
transfectants. Morphological changes in cells dying after CD40  Iigation 
with  5  b~g/ml anti-CD40  mAb G28-5  are shown in the  right panels: 
SVBOcD40 (ll, b), HeLacD40 (c, d), and A9cD40 cells (e,J~ were stained with 
acridine orange after an 18-h treatment with anti-CD40 mAb (b, d, )J or 
an isotype-matched control mAb (a, c, e) in the presence of 50 Ixg/rnl 
CHX. Cells were then analyzed  by fluorescence  microscopy at a 400-fold 
magnification. Cells treated with anti-CD40  mAb are shrunk and show 
condensed nuclei or nuclear fragmentation. 
CD40-, p55TNFR-,  and Fas-inducecl Cell Death Are Reg- 
ulated  Differently.  Sensitivity  to  p55TNFR  cytotoxicity 
can change  dramatically with changes  in the expression of 
inducible  protective  proteins  like  manganous  superoxide 
dismutase (52),  the plasminogen activator inhibitor-2 (53), 
and  the  zinc  finger protein A20  (54).  In some  cell types, 
when protein synthesis is intact, phorbol esters (i.e., PMA), 
IL-1  and,  paradoxically, TNF,  upregulate protective pro- 
teins. These render the cells resistant to a subsequent TNF 
challenge  in  the  presence  of CHX,  as  demonstrated  for 
SV80  and  HeLa  cells  (49).  Therefore,  we  tested  whether 
PMA,  IL-1,  and  TNF  pretreatment  also  conferred  resis- 
tance  to  CD40-mediated  killing  in  these  cells.  In  the 
SV80ct340  transfectants,  p55TNFR-mediated  killing  was 
markedly reduced after PMA, IL-1, or TNF prestimulation 
(Fig.  5,  middle); whereas CD40-mediated  cytotoxicity was 
not influenced by PMA or IL-1.  TNF  pretreatment  even 
enhanced  CD40  killing (Fig.  5,  top). A  dose  of mCD40L 
which  induced 40%  killing of naive  SV80co40  cells killed 
75%  of the  TNF-pretreated  targets.  Pretreatment  with  a 
ligand mimetic mAb against the  p55TNFR  also sensitized 
cells for CD40  killing, indicating that this effect was medi- 
ated  via  the  p55TNFR  (data  not  shown).  Similar results 
were obtained with HeLacD40 (data not shown).  The influ- 
ence  of PMA,  IL-1,  and  TNF  distinguished CD40  cyto- 
toxicity not only from p55TNFR, but also from Fas-medi- 
ated cytotoxicity as this was unaffected by all three reagents 
(Fig. 5, bottom). 
Synergism  between  CD40  and  p55TNFR  Cytotoxicity. 
The  observation that  target cell prestimulation with  TNF 
resulted in enhanced CD40 cytotoxicity raised the question 
whether p55TNFR  and CD40 synergized when stimulated 
simultaneously.  As  shown  in  Fig.  6  (left),  the  anti-CD40 
mAb G28-5 (1  ixg/ml) alone left 90% of the SV80cD40  cells 
viable. In combination with a marginally active TNF  dose 
(0.08  U/ml),  G28-5  killed  almost  50%  of  the  targets. 
When applied together with a half-maximal killing dose of 
TNF  (0.4 U/ml), G28-5 induced >90% killing. Inversely, 
in the presence of 1  Ixg/ml G28-5  the TNF  dose required 
for 50%  killing was  15-fold reduced and the dose yielding 
90%  cell death was 60-fold reduced (Fig. 6,  right). A  con- 
trol  experiment  with  the  ligand  mimetic  anti-p55TNFP, 
mAb, htr-9, revealed that the TNF effect was mediated via 
the p55TNFP,. (not shown). Synergism between CD40 and 
p55TNFP, killing was seen also with HeLacD40 and A9CD40 
(not shown) suggesting that it was not restricted to one par- 
ticular cell type. 
The question whether CD40 synergized with Fas killing 
could not be definitely answered. Augmentation of Fas cy- 
totoxicity  was  only  seen  in  IFN-y-pretreated  SV80cD40 
cells.  Here,  the  dose  of anti-Fas antibodies inducing half- 
maximal  or  90%  killing could be  7.5-fold  reduced  when 
CD40 was simultaneously stimulated with  1 t~g/ml G28-5 
antibody  (not  shown).  However,  this  effect  was  additive 
rather than synergistic. 
CD40  and  the  p55TNFR,  not  only  quantitatively  en- 
hanced each  other's cytotoxicity but also accelerated each 
162  CD40 Induces Apoptosis Figure 4.  CD40,  p55TNFtL, and 
Fas cytotoxicity  in murine A9 fibro- 
blasts with intact vs CHX-blocked 
protein synthesis. Cytotoxicity  assays 
were performed as described in Ma- 
terials and Methods in the presence 
(O, A) or the absence of CHX (O, 
A).  (Left) Paraformaldehyde-fixed 
BHKcD40  L cells (O,  O)  or BHKwt 
cells (A, A) were used to stimulate 
A9co40 cells at the indicated effector 
cell doses. The inset shows acridine 
orange-stained A9 cells after a 48-h 
treatment  with  anti-CD40  mAb 
(G28-5 at 5 p.g/ml) in the absence of CHX. Nuclear condensation  and fragmentation  are clearly  visible. (Middle)  TNF was used to activate the murine 
p55TNFF( in A9CD40  cells (50) (O, ~). (Right) A9 cells transfected with human Fas (51) were stimulated  with anti-Fas  mAb at the indicated concentra- 
tions (O, O). Cellular  viability  was determined 18 h (+CHX) or 48 h (-CHX) later by the neutral red uptake method. 
other's killing. Cell death in G28-5  (1  I~g/ml)-stimulated 
A9 fibroblasts was detectable after 6-9 h, increased within 
the next 16 h  in a linear fashion, and reached plateau levels 
at 60% killing (Table 1). At a TNF dose that was only mar- 
ginally cytotoxic  even  after  48  h,  addition  of the  anti- 
CD40 antibody led to clearly visible cell death as early as 4 h 
after stimulation (Table  1).  At  8  h  42%  of the  cells were 
killed and cell death gradually increased to 88% within 48 h 
(Table 1).  In the HeLa transfectants significant p55TNFR- 
or CD40-mediated killing in the presence of CHX was ob- 
served only after 10-12 h; however, the combined activa- 
tion of both receptors induced cell death after 6-8 h  (not 
shown). 
Metabolic Inhibitors Affect  CD40-mediated Killing Differently 
than p55TNFR-  and Fas-mediated  Cell Death.  p55TNFtk- 
mediated killing can be  blocked by various inhibitors of 
signal  transduction  (55).  Previously  such  inhibitors have 
been used to compare p55TNFtL and Fas cytotoxicity (56). 
To  determine whether or not CD40  cytotoxicity was  af- 
fected in the same manner as the p55TNFtL or Fas  cyto- 
toxicity, killing via all three  receptors  was  investigated in 
the  presence  and  absence  of several  metabolic inhibitors 
(Table 2).  All experiments were  performed  in A9  fibro- 
blasts with intact protein synthesis. Under these conditions 
some  reagents that  inhibit TNF cytotoxicity when RNA 
synthesis is  blocked,  i.e.,  the  phosphatidylcholine-specific 
phospholipase C  inhibitor D609 (56), had no effect at non- 
toxic  concentrations. The  oxygen radical scavenger BHA 
significantly reduced CD40 cytotoxicity suggesting that in 
A9  cells reactive oxygen intermediates might be involved 
not only in the p55TNFtL- but also in the CD40-activated 
cell death pathway. A  similar result was obtained with the 
phosphatase inhibitor vanadate which inhibited both CD40 
and p55TNFIL killing. Under these  conditions Fas  cyto- 
toxicity was  not affected  by BHA  or vanadate indicating 
that  CD40  cytotoxicity differed  from  Fas  killing. Use  of 
calcium modulators also suggested that CD40 signals were 
different from p55TNFR-mediated cell death signals. Both 
the calcium ionophore A23187 and the calmodulin inhibi- 
tor trifluoperazine decreased p55TNFiL cytotoxicity while 
CD40 and Fas killing were not inhibited at any concentra- 
tion tested. In fact, trifluoperazine enhanced CD40 and Fas 
cytotoxicity. 
Discussion 
The discovery of CD40 had an important impact on the 
understanding of B  cell  immunity (reviewed  in  [57]).  A 
preeminent function of CD40 is its ability to rescue germi- 
nal center B cells from undergoing apoptosis (12-14). Para- 
doxically, the intracellular domain of CD40 shares a struc- 
tural homology with the death domains of the p55TNFtL 
and Fas (9,  10).  This prompted us to investigate whether or 
Figure 5.  TNF prestimulation  induces resistance to p55TNFtL cyto- 
toxicity but enhances CD40-mediated cytotoxicity. SV80c,40 cells were 
pretreated with medium, PMA (5 ng/ml), IL-113 (0.15 ng/ml), or TNF 
(1,000 U/ml) for 3 h. The stimulation reagents were removed by two 
washing steps and 6 h later the cells were challenged  with 6 ￿  104/well 
BHKcD,mL cells (ll, top) (corresponding  to an E/T ratio of 1 : 1), with 200 
U/ml TNF(B, middle) or 40 ng/ml anti-Fas  mAb (m, bottom), always in 
the presence of 50 b~g/ml  CHX. Cellular  viability  was assessed after 18 h 
of incubation  by the neutral red uptake method. 
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Figure  6.  Synergism between 
CD40  and p55TNFR  cytotoxicity. 
(Left) SVS0cD40 cells were  treated 
with G28-5 at the indicated concen- 
trations in  the presence of TNF at 
0.4 U/ml (') or at 0.08 U/ml (&) 
or medium (O). (Right) Titration of 
TNF on SV80co40 cells in the pres- 
ence of G28-5 at 1 Ixg/ml (m) or at 
0.2 ~g/ml (A) or a control mAb at 1 
#.tg/ml (O). All assays were done in 
the presence of 50 Ixg/ml CHX. 
not CD40  could also mediate cytotoxicity. In three differ- 
ent cell lines which were chosen from two  different tissue 
origins (mesenchymal and epithelial) and two different spe- 
cies  (human  and  murine)  we  observed that  CD40  indeed 
induces cell death. Regardless of the cell type examined the 
dying cells showed typical morphological features of apop- 
tosis. 
In view of the structural relationship between the three 
cell  death-inducing  receptors  it  was  of interest  to  study 
whether  CD40,  p55TNFR,  and  Fas  killed  by  similar 
mechanisms.  Our initial findings supported this possibility. 
The cellular responsiveness to CD40 cytotoxicity showed a 
pattern similar to p55TNFR-  and Fas-mediated cytotoxic- 
ity: In SV80 and HeLa, CD40 elicited a cytotoxic response 
only in the presence of a protein synthesis inhibitor, while 
the routine A9 fibroblasts were efficiently killed with intact 
or blocked protein synthesis. This demonstrated that CD40 
stimulation  activates  a  preformed  death  program  which 
does not require the synthesis of novel proteins. Moreover, 
Table 1.  Acceleration of TNF Killing by Simultaneous CD40 
Ligation in A9co4o Cells 
Killing after 
4h  8h  12h  48h 
Percent cell death 
Medium  <5  <5  <5  <5 
TNF  <5  <5  <5  14.2 
(_+2.0) 
Anti-CD40  <5  15.4  25.5  59.7 
(_+3.0)  (_+4.1)  (_+3.1) 
TNF +  21.6  42.6  51.0  88.6 
anti-CD40  (_+8.2)  (_+6.2)  (_+4.9)  (_+1.0) 
A9CD40 cells were treated in the absence of CHX with anti-CD40  mAb 
G28-5 at 1 p,g/ml, 200 U/ml TNF, the combination of both, or me- 
dium as a control. Cell death was determined after the indicated time 
intervals. Presented are the mean values of quadruplicate determinations 
(+ SD) of one representative experiment. 
in some cell types constitutive expression of resistance pro- 
teins  seemed  to  interfere  not  only with  p55TNFR-  and 
Fas-induced cytotoxicity (49, 58) but also with the CD40- 
induced cell death pathway. 
Despite  these  similarities, further  experiments  revealed 
several differences in  CD40-  and p55TNFR-induced  cell 
death:  (a)  while  TNF  killed  the  murine  A9  fibroblasts 
markedly better in the presence of CHX,  CD40 cytotoxic- 
ity was  much  stronger in the absence of CHX.  This sug- 
gested  that  in  A9  cells  CD40  not  only  triggered  a  pre- 
formed death program but also may have induced proteins 
that supported the induction of cell death.  (b)  Treatments 
that induced resistance to p55TNFR  cytotoxicity failed to 
protect against cD40  and  Fas killing. For example, TNF, 
which  paradoxically  induces  resistance  to  p55TNFR,- 
mediated cell death, even sensitized cells for CD40  killing. 
(c)  Simultaneous  activation  of the  p55TNFR  and  CD40 
was synergistic resulting both in enhanced and accelerated 
killing. This synergism did not result from receptor upreg- 
ulation since it was also observed in the presence of CHX. 
(d) CD40-, p55TNFR-,  and Fas-mediated killing were in- 
fluenced differently by several metabolic inhibitors. Unlike 
Fas  killing,  CD40-  and  p55TNFP,,-mediated  cytotoxicity 
were both inhibited by the radical scavenger BHA and the 
phosphatase inhibitor vanadate in A9 cells with intact pro- 
tein synthesis. However, similar to Fas but unlike p55TNFR, 
CD40 killing could not be blocked with modulators of cal- 
cium metabolism, such  as the  calcium ionophore A23187 
or the calmodulin inhibitor trifluoperazine. These findings 
suggest that the cell death pathway of CD40  may partially 
overlap but is not  identical with  the  signaling pathway  of 
either p55TNFR  or Fas. 
Molecular evidence for the differences in the  cell death 
pathways triggered by p55TNFR  and Fas was recently pro- 
vided in several studies describing three receptor-associated 
proteins  that  can  initiate  cell  killing  (59,  62).  Although 
these proteins are also homologous to the death domains of 
p55TNFR  and Fas, they specifically interact only with in- 
dividual receptors. Thus it emerges that the cell death path- 
ways of the p55TNFR  and  Fas differ in proximal events, 
nevertheless they seem to converge in an  IL-l-converting 
164  CD40 Induces Apoptosis Table 2.  Influence of Various Metabolic lnhibitors on CD40, 
p55TNFR, and Fas-mediated Killing in A9 Transfectants 
Killing via 
Inhibitors*  CD40  p55TNFR  Fas 
Viability (percent control) 
No inhibitor  3.5  5.7  1.8 
(-+0.S)  (- 1.3)  (-+0.6) 
BHA  50 I~M  32.2  46.5  1.4 
(-----4.3)  (+2.7)  (+1.0) 
Vanadate  12.5  p,M  20.2  39.4  1.3 
(+--1.7)  (+3.2)  (+1.0) 
A23187  0.1  txM  1.4  12.3  1.5 
(-+0.3)  (+-1.6)  (-+0.8) 
Trifluoperazine  2.5 btM  2.7  17.4  1.0 
(-+0.3)*  (-+1.9)  (+1.8)* 
CD40  was  stimulated  in  A9cD40 cells with  paraformaldehyde-fixed 
BHKcD40  t cells (at 6  X  104/well), the p55TNFR  with  1,000 U/ml 
TNF. A9 cells transfected with human Fas (57) were activated with 200 
ng/m_l anti Fas mAb. Results are presented as mean values of eight rep- 
licates (+SD). 
*  Inhibitors were  added simultaneously with the indicated treatments 
and remained in the culture medium during the whole assay period. 
Cell viability with inhibitors alone was 95.5% (-+5.4) for BHA, 93.7% 
(-+5.7) for vanadate, 97.5% (-+6.8) for A23187, and 76.5% (-+8.7) for 
trifluoperazine. 
SAt lower concentrations  of BHKcD40  t  (2  X  10a/well) and  anti-Fas 
mAb (40 ng/ml)  trifluoperazine enhanced  CD40- and  Fas-mediated 
cytotoxicity  by 55.4 and 66.1%, respectively. 
enzyme-dependent route (63, 64). Therefore, it will be in- 
teresting  to  search  for  CD40-specific  associated  proteins 
that  are involved in cell death signaling and to  determine 
whether  CD40  killing also  uses  an  IL-l-converting  en- 
zyme-dependent pathway. 
Recent studies suggest that CTL killing relies mainly on 
the  action of perforin and  Fas (65);  however,  the way in 
which a particular target cell is eliminated depends not only 
on the mediators expressed by the effector cell but also on 
the responsiveness of the target cell. Since activated T  cells 
express not only Fas ligand but also TNF  and  CD40L  on 
their surface it is possible that all three ligands constitute a 
cytotoxic  triad.  The  potency  of this  triad  is  further  en- 
hanced by IFN-% a secretory product of activated T  cells. 
IFN-'y sensitizes not only for p55TNFR  (66)  and Fas (67) 
but also for CD40-mediated killing as shown here. Such an 
arsenal in  CTL  would clarify their broad target cell spec- 
trum  and  efficient  rate  of  target  cell  elimination.  Fur- 
themore,  target cell escape from receptor-mediated killing 
would  occur  only  when  all  three  cytotoxic  mechanisms 
fail. Thus, a CD40-positive tumor cell that became resistant 
to Fas cytotoxicity, e.g., via downregnlation of the receptor 
or via the  upregulation  of inhibitory proteins like the re- 
cently cloned Fas-associated protein FAP-1  (68),  may still 
be susceptible to TNFR  or CD40 killing. Since CD40 me- 
diates cell death in transformed cells, it can even be specu- 
lated  that  tumor-infiltrating  lymphocytes  may  use  this 
mechanism for the elimination of some tumor cells in vivo. 
In view of our findings, it will be important to determine 
whether  the  cytotoxic potential of CD40  can  be  used  in 
cancer therapy. 
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